rcent to $816.7 million
. U.S. Forteo sales for 2009 were $518.3 million
, a 6 percent increase driven by higher prices, partially offset by lower demand. Forteo sales outside the U.S. were $298.4 million
, a 3 percent increase driven by increased demand and increased prices, partially offset by the unfavorable impact of foreign exchange rates.
During the fourth quarter of 2009, Strattera generated $162.2 million of sales, an increase of 10 percent compared with the fourth quarter of 2008. U.S. sales increased 5 percent to $117.5 million, due to higher prices. Sales outside the U.S. increased 26 percent, to $44.7 million, driven by increased demand, the favorable impact of foreign exchange rates and higher prices.
For the full-year of 2009, worldwide Strattera sales increased 5 percent to $609.4 million. U.S. Strattera sales for 2009 were $445.6 million, a 2 percent increase driven by higher prices, partially offset by lower demand. Strattera sales outside the U.S. were $163.7 million, a 15 percent increase driven by increased demand and increased prices, partially offset by the unfavorable impact of foreign exchange rates.
Lilly recognizes in revenue its 50 percent share of Byetta's gross margin in the U.S., 100 percent of Byetta sales outside the U.S., and its sales of Byetta pen delivery devices to its partner, Amylin Pharmaceuticals. For the fourth quarter, Lilly recognized total revenue of $120.5 million for Byetta, an increase of 17 percent.
Worldwide sales of Byetta were $203.6 million in the fourth quarter of 2009, a 9 percent inPage: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 Related medicine technology :1
. FDA Approves Lillys Osteoporosis Drug EVISTA(R) (raloxifene HCl) to Reduce The Risk of Invasive Breast Cancer in Two Populations of Postmenopausal Women2
. Lilly Files for European Approval of ALIMTA(R) (pemetrexed for injection) for First-Line Treatment of Non-Small Cell Lung Cancer3
. Lilly and Glenmark Pharmaceuticals Announce License Agreement4
. Lilly Receives NCQA Design Certification for Depression Care Management Program5
. JDRF and Lilly Partner to Fund Research to Identify Beta Cell Biomarkers6
. FDA Grants Priority Review for Daiichi Sankyo, Lilly Drug, prasugrel7
. Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release8
. Lilly and Transition Therapeutics Announce Licensing and Collaboration Agreement9
. Lilly Launches Its First Phase III Trial for Treatment of Alzheimers Disease10
. Daiichi Sankyo/Eli Lillys Effient and Astrazenecas Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction11
. Lilly Submits Cymbalta(R) Supplemental New Drug Application for Chronic Pain to U.S. Food and Drug Administration